VIPIDIA is a prescription medication primarily used in the management of type 2 diabetes mellitus. It contains the active ingredient alogliptin, which belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. By inhibiting the DPP-4 enzyme, VIPIDIA increases the levels of incretin hormones in the body, which in turn stimulates the release of insulin in response to high blood glucose levels and decreases the amount of glucose produced by the liver. This dual action helps in controlling blood sugar levels, thereby assisting in the management of type 2 diabetes. VIPIDIA is often prescribed in combination with diet and exercise and may also be used in conjunction with other diabetes medications to achieve better glucose control.